Vivek Tandon, Vice President, Primus Partners, shares his view on the opportunities for Indian pharma companies in the semaglutide market. He highlights that India, being the world’s largest supplier of generics with over 20 percent share, is well positioned to disrupt the global market with high-quality semaglutide generics once the drug goes off patent. He added that Indian pharmaceutical majors have been preparing for this opportunity for several years.